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The single-dose pharmacokinetics of marbofloxacin was studied in clinically normal foals
after intravenous and intramuscular administration of 5 mg of marbofloxacin/kg of body
weight. Marbofloxacin concentrations were determined by microbiological assay method.
The disposition of marbofloxacin was best described by a two-compartment open model
after a single intravenous injection while, by a one-compartment open model after intra-
muscular administration. The distribution half-life, elimination half-life, mean residence
time of marbofloxacin after intravenous injection were 0.27, 6.4, 6.8 h after 5 mg/kg dose.
Following intramuscular administration, the drug absorbed at a fast rate as indicated by
short absorption half-life (t0.5(ab)) of 0.26 h. The drug was eliminated at a slow rate with an
elimination half-life t0.5(el) of 7.16 h after 5 mg/kg dose. The extent of serum protein binding
was 27.5%. These results indicate that a dose of 5 mg of marbofloxacin/kg administered as
a single dose once daily could be useful in the treatment of diseases caused by sensitive
pathogens in foals after specific assessments.
Copyright 2013, Beni-Suef University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction against susceptible target microorganisms (Brown, 1996).Fluoroquinolones are antimicrobial drugs that generally have
very good activity against a broad spectrum of aerobic gram-
negative including Pasteurella spp., some gram-positive bac-
teria and against mycoplasma (Hannan et al., 1997). Fluo-
roquinolones have other desirable characteristics such as
large volumes of distribution, low serum protein binding and
relatively low minimum inhibitory concentrations (MIC)982.
Tohamy).
i-Suef University
sevier
13, Beni-Suef University.Marbofloxacin is a second generation fluoroquinolone
(Martinez et al., 2006) approved exclusively for animal clinical
use. It has broad spectrum bactericidal activity against Gram-
negative bacteria, Gram-positive bacteria and Mycoplasma
species (Drugeon et al., 1997; Meunier et al., 2004). It has some
pharmacokinetic properties such as a long elimination half-
life (t0.5(el)), and high bioavailability after oral administration
(Heinen, 2002). The pharmacokinetics of marbofloxacin hasProduction and hosting by Elsevier B.V. All rights reserved.
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et al., 2007) and horses (Bousquet-Melou et al., 2002;
Carretero et al., 2002; Peyrou et al., 2004) but no data are
available in foals. Consequently, the purpose of the present
study was to investigate the bioavailability and pharmacoki-
netics of marbofloxacin in foals following a single intravenous
(IV) and intramuscular (IM) administration of 5 mg/kg of body
weight.2. Materials and methods
2.1. Drug
Marbofloxacin was used as a 10% injectable aqueous solution
obtained from Veterinary Pharmaceutical Laboratories,
France (Marbocyl, Vetoquinol, Lure, France). Marbofloxacin
standard was provided by Vetoquinol (Lure, France).
2.2. Animals
Six clinically healthymale and female Egyptian foals weighing
200e250 kg b. wt. (9e11 months of age) were used. Animals
were kept under good hygienic condition and none of them
were treated with antibiotics for one month prior to the trial.
2.3. Experimental design
The foals were given a single intravenous (into the right ju-
gular vein) and intramuscular (into the deep gluteal muscle of
hindquarters) dose of 5 mg/kg 10% aqueous solution of mar-
bofloxacin (Carpenter et al., 2009) with a two weeks washout
period between each route. Blood samples were collected
from the left jugular vein just before drug administration and
at 0.083, 0.167, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12 and 24 h after drug
administration. The blood was allowed to clot at room tem-
perature, and then the serumwas separated by centrifugation
at 3000 g for 15 min. Serum samples were stored at 20 C
until assayed. Three foals showed only slight swelling at the
site of injection and diarrhea in one foal.
2.4. Drug assay
Marbofloxacin concentrations in serum samples were deter-
mined by the microbiological assay method described by Tsai
and Kondo (2001) using Escherichia coli (ATCC 25922) as a test
organism. Standard curves were constructed using
antibacterial-free serum collected from foals. Six wells, 8 mm
in diameter were cut at equal distances in standard petri
dishes containing 25 ml seeded agar. The wells were filled
with 100 ml of either the test samples or marbofloxacin stan-
dards. The plates were incubated at 37 C for 24 h. The inhi-
bition zone diameters were measured and the marbofloxacin
concentrations in the test samples were calculated from the
standard curve. The limit of detection of the marbofloxacin
assay was 0.02 ug/ml. Semi-logarithmic plots of the inhibition
zone diameter versus standard marbofloxacin concentrations
in serum were linear with typical correlation coefficient of
0.97. The extent of protein binding was determined in vitro
according to the method described previously by Craig andSuh (1991) with marbofloxacin concentrations 0.02, 0.04,
0.08, 0.156, 0.313, 0.625, 1.25, 2.5 and 5 ug/ml in serum and
phosphate buffered saline (pH 7.2). This method was based on
the diffusion of free antibiotic into the agar medium. The
differences in the diameters of the inhibition zones between
the solutions of the drug in the buffer and serum samples
were then calculated according to the following equation:
Protein binding% ¼ðZone of inhibition in buffer
 Zone of inhibition in serum=Zone
of inhibition in bufferÞ  100
2.5. Pharmacokinetic analysis
Serum concentrations of marbofloxacin after IV and IM ad-
ministrations were subjected to a compartmental analysis
using a nonlinear least-squares regression analysis. The
analysis was done with the help of a computerized curve-
stripping software package (R STRIP, Version 5.0; Micromath
Scientific Software, Salt Lake City, UT, USA). Data were exam-
ined by sequential weighted nonlinear regression. Mono-
exponential and bi-exponential equations were fitted to indi-
vidual serum concentration-time data. Akaike’s Information
Criterion (Yamaoka et al., 1978), residual sum of squares, and
analysis of the residual’s plots were used to discriminate be-
tweenmodels (Powers, 1990). Following IV injection, the serum
concentrationetime relationship was best estimated as a two-
compartment open model system (Baggot, 1978) according to
the following bi-exponential equation: Cp ¼ Aeat þ Bebt,
whereCp is the concentrationofdrug in the serumat time t; A is
the intercept of the distribution phase with the concentration
axis expressed as mg/ml-; B is the intercept of the elimination
phase with the concentration axis expressed as mg/ml; a is the
distribution rate constant expressed in units of reciprocal time
(h1); b is the elimination rate constant expressed in units of
reciprocal time (h1); and e is the natural logarithm base.
After IM administration, data was analyzed by adopting a
one-compartment model. This program also calculated non-
compartmental parameters using the statistical moment the-
ory (Gibaldi and Perrier, 1982). The Cmax (maximum serum con-
centration) and tmax (time of maximum serum concentration)
were obtained from individual tabulated values (observed
values).The terminaleliminationhalf-life (t0.5(el)) andabsorption
half-life (t0.5(ab)) were calculated as ln2/Kel or ln2/Kab, respec-
tively,whereKel andKab are the elimination and absorption rate
constants, respectively. The area under serum concentration-
time curve (AUC) and area under the first moment curve
(AUMC) were calculated using the trapezoidal method and
extrapolation to infinity (Baggot, 1978).Themeanresidence time
(MRT) was calculated as MRT ¼ AUMC/AUC. The total body
clearance (ClB) was calculated as ClB ¼ Dose/AUC and the abso-
lute bioavailability (F) as F ¼ AUCi.m/AUCi.v$100 (Gibaldi and
Perrier, 1982). The results obtained were expressed as mean
and standard error (SE). Standard errors were calculated from
themean data according to Snedecor and Cochran (1976).
2.6. Pharmacodynamic analysis
Several pharmacodynamic (PD) parameters including the
maximum serum concentration/minimum inhibitory
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Fig. 1 e Semi-logarithmic graph depicting the time-
concentration of marbofloxacin in serum of normal foals
after a single intravenous (D) and intramuscular (,)
injection of 5 mg/kg b wt. (n [ 6).
b e n i - s u e f un i v e r s i t y j o u rn a l o f b a s i c a n d a p p l i e d s c i e n c e s 2 ( 2 0 1 3 ) 4 6e5 048concentration (Cmax/MIC) ratio and the area under the 24-h
serum concentration-time curve/MIC (AUC0e24h/MIC) ratio
have been proposed to predict the antimicrobial efficacy of
fluoroquinolones in vivo (Turnidge, 1999;McKellar et al., 2004).
The PD efficacy of marbofloxacin was determined by calcu-
lating the Cmax/MIC and AUC/MIC ratios following IM admin-
istration using the hypothetical MIC90 of marbofloxacin
against Enterobacteriaceae 0.027 mg/ml (Bousquet-Melou et al.,
2002; Peyrou et al., 2004).3. Results
The mean serum concentration time courses of marbo-
floxacin after intravenous and intramuscular administration
are depicted in (Fig. 1). Pharmacokinetic parameters are
showed in (Table 1). After intravenous administration of 5mg/
kg b. wt., the marbofloxacin serum concentration time data fit
two-compartment open model. The distribution half-life,
elimination half-life, mean residence time of marbofloxacin
after intravenous injection were 0.27, 6.4, 6.8 h. Following
intramuscular administration, the drug absorbed at a fast rateTable 1 e Pharmacokinetic parameters of marbofloxacin follow
administration of 5 mg/kg in foals (n[ 6).
Parameter Unit IV
Cpo mg ml
1 4.1  0.04
A mg ml1 2.6  0.01
B mg ml1 1.5  0.04
a h1 2.6  0.05
b h1 0.11  0.002
K12 h
1 1.4  0.02
K21 h
1 1.04  0.04
Kel h
1 0.27  0.004
t0.5(a) h 0.27  0.005
t0.5(b) h 6.4  0.08
Vc L kg
1 1.2  0.007
Vdss L kg
1 2.3  0.09
ClB L kg
1 h1 0.34  0.003
MRT h 6.8  0.12
AUC0e24 mg*h/ml 14.7  0.27
AUMC mg*h2/ml 94.84  2.9as indicated by short absorption half-life (t0.5(ab)) of 0.26 h. The
drug was eliminated at a slow rate with an elimination half-
life t0.5(el) of 7.16 h. The extent of serum protein binding was
27.5%.
Cp concentration at zero time (immediately after single IV
injection);A, B zero-time intercepts of the biphasic disposition
curve; a, b hybrid rate constants representing the slopes of
distribution and elimination phases, respectively; k12 first-
order constant for transfer from central to peripheral
compartment; k21 first-order constant for transfer from pe-
ripheral to central compartment; Kel elimination rate con-
stant; t0.5(a) distribution half-life; t0.5(b) elimination half-life;
MRT mean residence time; AUC0-24 area under serum
concentration-time curve; AUMC area under moment curve;
Vc apparent volume of the central compartment; Vdss volume
of distribution at steady state; ClB total body clearance. kab
first-order absorption rate constant; Cmax maximum serum
concentration; Tmax time to peak serum concentration; t0.5(ab)
absorption half-life; t0.5(el) elimination half-life; MAT mean
absorption time; F fraction of drug absorbed systemically after
IM injection.4. Discussion
Data on the pharmacokinetics ofmarbofloxacin in equines are
limited, and specific pharmacokinetic data for foals are lack-
ing. Therefore, foals were treated with marbofloxacin at the
recommended dose of 5mg/kg b. wt. either IV or IM. The study
revealed that serum marbofloxacin concentrations versus
time decreased in a bi-exponential manner following intra-
venous injection, demonstrating the presence of distribution
and elimination phases and justifying the use of two-
compartment open model. This finding is in agreement with
other pharmacokinetic study of the drug in calves (Ismail and
El-Kattan, 2007). Serum concentration profiles showed a rapid
initial distributive phase, followed by a slower elimination
phase with an estimated mean elimination half-life of 6.4 h.
This finding is similar to that recorded for the drug in horseing a single intravenous (IV) and intramuscular (IM)
Parameter Unit IM
Cmax mg ml
1 1.14  0.02
Tmax h 1.3  0.004
Kab h
1 2.7  0.02
Kel h
1 0.10  0.003
t0.5(ab) h 0.26  0.001
t0.5(el) h 7.16  0.11
AUC0-24 mg*h/ml 12.6  0.31
AUMC mg*h2/ml 96.2  3.4
MRT h 8.01  0.21
MAT h 1.21  0.22
F % 85.7  0.09
Cmax/MIC e 42.2  0.27
AUC/MIC e 466.7  11
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roquinolones have a long serum half-life making them suit-
able for once or twice a day administration (Vancutsem et al.,
1990). The distribution of marbofloxacin in the body of foals
recorded in this study was more than unity (>one L/kg)
following intravenous injection (2.3 L/kg), indicated that the
drug was extensively distributed to extra-vascular tissues and
this result supported by Baggot (1978). In the present study,
the total body clearance (Cltot) 0.34 L/kg
/h agreed with that
reported in horse 0.25 L/kg/h (Bousquet-Melou et al., 2002).
Following intramuscular administration, the drug absor-
bed at a fast rate as indicated by an absorption half-life (t0.5(ab))
of 0.26 h. The pharmacokinetic properties of fluoroquinolones
include rapid absorption (Roland et al., 1995). This may be due
to the result of continued absorption of marbofloxacin from
the site of intramuscular administration during the elimina-
tion phase, thereby, prolonging the t0.5(el) of the drug. Ab-
sorption limits drug elimination (Gibaldi and Perrier, 1982).
The drug was eliminated at a slow rate with an elimination
half-life t0.5(el) of 7.16 h. Also, this result supported by longer
MRT of 8.01 h. The systemic bioavailability of marbofloxacin
after IM administration was 85.7%, similar to that reported in
horse 87.9% (Carretero et al., 2002). These values indicates
high rate of absorption of the drug from that injection site. The
in vitro protein binding tendency of marbofloxacin to foal’s
serum proteins was 27.5%. This indicated that the drug is
slightly bound to serum proteins. It was stated that fluo-
roquinolones binding to serum proteins is relatively low up to
30% (Wise et al., 1984).
The minimum inhibitory concentrations (MICs) of marbo-
floxacin against foal’s bacterial isolates have not yet been
determined. The MIC of the drug was recorded to be
0.027 ugml1 against Enterobacteriaceae (Bousquet-Melou et al.,
2002; Peyrou et al., 2004). Fluoroquinolones are active against
bacterial pathogens in a concentration-dependent manner.
Various empirical PK/PD ratios have been proposed to predict
the success or failure of therapy. The effective use of the flu-
oroquinolones against clinically important animal pathogens
is dependent on designing dosages that attain serum Cmax/
MIC ratios of 10:1 or AUC/MIC ratios of 125:1 (Walker, 2000;
Toutain et al., 2002). Marbofloxacin PK/PD integration after
IM administration revealed values for Cmax/MIC and AUC/MIC
ratios of 42.2 and 466.7 which indicate the excellent PD char-
acteristics of the drug in foals.
The use of other fluoroquinolones has been associated
with arthropathy in young animals of various species
including foals (Vivrette et al., 2011), thus additional studies
are necessary to confirm that marbofloxacin does not cause
arthropathy before its use can be recommended in foals.
In conclusion, a dose of 5 mg of marbofloxacin/kg admin-
istered as a single dose once daily could be useful in the
treatment of diseases caused by Enterobacteriaceae in foals.Acknowledgments
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